0000914190-20-000237.txt : 20200708 0000914190-20-000237.hdr.sgml : 20200708 20200708174743 ACCESSION NUMBER: 0000914190-20-000237 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200706 FILED AS OF DATE: 20200708 DATE AS OF CHANGE: 20200708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hippel James CENTRAL INDEX KEY: 0001603594 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 201019090 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-07-06 0000842023 BIO-TECHNE Corp TECH 0001603594 Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS MN 55413 0 1 0 0 Chief Financial Officer Common Stock 2020-07-06 4 M 0 21502 108.49 A 30809 D Common Stock 2020-07-06 4 S 0 9571 270.4532 D 21238 D Common Stock 2020-07-06 4 S 0 3781 271.5333 D 17457 D Common Stock 2020-07-06 4 S 0 4947 272.338 D 12510 D Common Stock 2020-07-06 4 S 0 1934 273.7115 D 10576 D Common Stock 2020-07-06 4 S 0 1269 274.5177 D 9307 D Common Stock 2020-07-07 4 M 0 2577 108.49 A 11884 D Common Stock 2020-07-07 4 S 0 414 270.5567 D 11470 D Common Stock 2020-07-07 4 S 0 1663 271.4019 D 9807 D Common Stock 2020-07-07 4 S 0 500 272.26 D 9307 D Stock Options (Right to Buy) 108.49 2020-07-06 4 M 0 21502 0 D 2022-08-07 Common Stock 21502 18486 D Stock Options (Right to Buy) 108.49 2020-07-07 4 M 0 2577 0 D 2022-08-07 Common Stock 2577 15909 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 30400 30400 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 40533 40533 D Restricted Stock Units Common Stock 4438 4438 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 24460 24460 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 32613 32613 D Restricted Stock Units Common Stock 3383 3383 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 18066 18066 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 24089 24089 D Restricted Stock Units Common Stock 3938 3938 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 19936 19936 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 26581 26581 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0000 to $270.9800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0000 to $271.9900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0100 to $272.9500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.2300 to $274.2200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.2700 to $275.0300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0700 to $271.0500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.0700 to $271.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.0900 to $272.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Fully exercisable. Options to purchase 10,134 shares vest on 8/18/2017 and options to purchase 10,133 shares vest on each of 8/18/2018, 8/18/2019 and 8/18/2020. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. /s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed. 2020-07-08